SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 27th, 2016 • Eyegate Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 27, 2016, between EyeGate Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON STOCK PURCHASE WARRANT EYEGATE PHARMACEUTICALS, INC.Common Stock Purchase Warrant • June 27th, 2016 • Eyegate Pharmaceuticals Inc • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December 30, 2016 (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from EyeGate Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
June 24, 2016 STRICTLY CONFIDENTIAL Stephen From President and Chief Executive Officer EyeGate Pharmaceuticals, Inc.Exclusive Agency Agreement • June 27th, 2016 • Eyegate Pharmaceuticals Inc • Pharmaceutical preparations • New York
